BRAF inhibitors vemurafenib and dabrafenib have become the standard of care for treatment of stage IV metastatic melanoma harboring a BRAF mutation. Panniculitis is a rare but known adverse side effect of these agents and presents with tender erythematous nodules. These nodules may demonstrate uptake on 18F-FDG PET/CT, whichmay mimic metastatic disease in patients undergoing treatment. We present a case of BRAF inhibitor-induced panniculitis in a patient with stage IV metastatic melanoma and discuss the imaging findings on 18F-FDG PET/CT.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging